Protagonist Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

PTGX$135.90+2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)


· · September 30, · · December 31,
	2024		2023
Assets
Current assets:
Cash and cash equivalents		$131,121		$186,727
Marketable securities		337,600		154,890
Receivable from collaboration partner		—		10,000
Prepaid expenses and other current assets		8,048		3,960
Total current assets		476,769		355,577
Marketable securities - noncurrent		114,560		—
Property and equipment, net		2,468		1,195
Restricted cash - noncurrent		225		225
Operating lease right-of-use asset		9,835		954
Total assets		$603,857		$357,951
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable		$3,049		$772
Payable to collaboration partner		—		3
Accrued expenses and other payables		20,739		19,358
Deferred revenue		19,696		—
Income taxes payable		1,049		—
Operating lease liability		45		1,141
Total current liabilities		44,578		21,274
Deferred revenue - noncurrent		16,509		—
Operating lease liability - noncurrent		10,855		—
Total liabilities		71,942		21,274
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding		—		—
Common stock, $0.00001 par value, 180,000,000 and 90,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 59,521,903 and 57,708,613 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively		1		1
Additional paid-in capital		1,002,774		952,491
Accumulated other comprehensive income (loss)		1,336		(105)
Accumulated deficit		(472,196)		(615,710)
Total stockholders’ equity		531,915		336,677
Total liabilities and stockholders’ equity		$603,857		$357,951

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.